Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma
Yasuyoshi Sato(The Cancer Institute Hospital), Shunji Takahashi(Japanese Foundation For Cancer Research), Junichi Tomomatsu(The Cancer Institute Hospital), Keiko Hayakawa(Cancer Institute (WIA)), Naoki Fukuda(The Cancer Institute Hospital), Makiko Ono(The Cancer Institute Hospital), Kenji Nakano(National Center for Global Health and Medicine), Seiichi Matsumoto(Fukuda Denshi (Japan)), Taisuke Tanizawa(Japanese Foundation For Cancer Research), Akihiro Ohmoto(Japanese Foundation For Cancer Research), Mayu Yunokawa(Japanese Foundation For Cancer Research), Xiaofei Wang(Duke University), Tetsuya Urasaki(Japanese Foundation For Cancer Research), Keisuke Ae(The Cancer Institute Hospital), Yuki Funauchi(Japan Association for Development of Community Medicine)
Cited by 8
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264